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WS14.1 Day-time variability and short term effect of chest
physiotherapy on multiple breath nitrogen washout in
children with cystic ﬁbrosis
C. Voldby1, K. Green1, T. Kongstad1, L. Philipsen1, F.F. Buchvald1, M. Skov1,
T. Pressler1, P. Gustafsson2, K.G. Nielsen1. 1Copenhagen University Hospital,
Rigshospitalet, CF-Center Copenhagen, Pediatric Pulmonary Service, Copenhagen,
Denmark; 2Central Hospital Sko¨vde, Department of Pediatrics, Sko¨vde, Sweden
Objectives: Multiple breath nitrogen washout (N2MBW) is increasingly used
in clinical and research studies world-wide to measure ventilation distribution
inhomogeneity (VI) and peripheral airway involvement in patients with Cystic
Fibrosis (CF). Chest physiotherapy (CPT) is an integrated part of daily CF treatment
used to clear the airways of mucus. The short-term effects of CPT on VI are
unknown. The present study aimed to determine day-time variability and short-
term effects of CPT on VI measured by N2MBW in children with CF.
Methods: Prospective, controlled, intervention study of 10 randomly selected
children with CF performing N2MBW, morning and afternoon on 3 visits one
month apart. Patients performed extensive CPT supervised by a physiotherapist
immediately before N2MBWafternoon at visit 2 and immediately before both
N2MBWmorning and N2MBWafternoon at visit 3, but refrained from CPT on other
occasions. All patients were clinically stable at measurements.
Results: Eight of 10 children with CF [mean age 10.5 years (SD= 2.9)] performed
all repeated N2MBWs. Neither CPT nor time of day affected N2MBW outcome
values. For the primary outcome Lung Clearance Index [mean 9.45 (SD= 1.91)],
Dmorning–afternoon was 0.16, 0.10 and 0.01 (all non-signiﬁcant) at visit 1, 2 and 3
respectively.
Conclusion: In this study CPT showed no short-term effects on any N2MBW
outcomes, supporting previous ﬁndings. Additionally, timing of measurement did
not affect N2MBW and may thus be ignored. Our results are relevant when
designing and interpreting future longitudinal studies.
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Objectives: The phase III trial of inhaled dry powder Bronchitol showed sustained,
clinically meaningful beneﬁt in patients with cystic ﬁbrosis (CF) (Bilton, 2011).
NICE (2012) have approved Bronchitol as an add-on therapy to best standard care
in adults with CF. The aim was to assess the tolerability of inhaled dry powder
Bronchitol in adult CF patients.
Methods: A retrospective review of the Bronchitol Inhaled Dose Assessments
(BIDA) completed March 2013 to January 2014.
Results: 52 BIDAs were completed over 11 months. The median (range) age was 28
(17−52) years and median (IQR) FEV11.4 (1.12–2.16) L, 44 (30−50) % predicted.
4 (7.6%) patients failed the assessment, 3 with drop in spirometry and 1 with
excessive coughing. Of those who passed the BIDA (n = 48), 7 (15%) stopped
taking Bronchitol due to either tightness (n = 5), adherence (n = 1) or feeling no
improvement (n = 1). 32 patients had improved median FEV1 from 1.47 to 1.6 after
6 weeks of taking Bronchitol, but this was not statistically signiﬁcant (p = 0.56). 18
patients completed the BIDA during a hospital stay for an infective exacerbation
and all passed the BIDA. 14 patients had a FEV1 at the start of the BIDA of
<30% predicted, 1 BIDA fail, 17 had FEV1 30−50% predicted, 1 BIDA fail, and
21 had FEV1 >50% predicted, 2 BIDA fails.
Conclusion: Bronchitol was well tolerated in our adult CF patients, 92% of patients
passed the BIDA. In the small subgroups of exacerbators or those with severe lung
function impairment there was no evidence of a higher failure rate however further
investigation with greater numbers of patients is warranted.
WS14.3 UK use of bronchial challenge for new therapies
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Introduction: Best practice guidelines indicate that CF patients starting new
nebulised medication should ﬁrst undergo a bronchial challenge (BC) test (including
pre and post spirometry), for safety reasons to prevent unacceptable side-effects,
and to prevent the dispensation of costly therapy which will not be used. Despite
these recommendations, we had the impression that there was a wide variation in the
use of BC tests. We therefore undertook a survey to identify current UK practice.
Method: A structured on-line survey was circulated via the CF Physiotherapy
National Group, representing UK-wide Regional and Network Care CF Units,
asking about the use and nature of new therapy BCs.
Results: Of 49 respondents, 33 were Regional Units, 13 Network Care, and 3
others. Eighteen cared for adults, 21 for children, and 10 both age groups. Overall,
40 (83%) always performed BC, 10 (11%) sometimes, but 3 (6%) never carried
them out. BC was carried out by physiotherapists (65%) or CF nurses (25%), with
respiratory nurses and others performing the remainder. As regards tests performed,
45 (92%) carry out pre and post spirometry (44 considered a 10% fall as signiﬁcant),
31 (63%) auscultate, 31 (63%) monitor oxygen saturation, and 23 (47%) routinely
pre-bronchodilate. Challenge tests are carried out for inhaled antibiotics at 41 units
(84%) and hypertonic saline in 47 (96%).
Conclusion: While most CF units carry out BCs (the majority done by physiother-
apists), some do not follow this best practice, which has implications for patient
safety and the correct use of often costly therapy. Further educational work needs
to be done to improve this important aspect of CF patient care.
WS14.4 Analysis of expiratory ﬂow rates used in autogenic drainage.
Are they sufﬁciently high to mobilize secretions?
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Autogenic Drainage (AD) is based on the use of expiratory airﬂow to mobilize
secretions proximally. These rates need to exceed 30−60L/min in order to mo-
bilize secretions. However, no-one has examined whether this rate is met while
performing AD.
Objective: To examine expiratory ﬂow rates used during coughing, hufﬁng and AD.
Methods: 14 CF patients, aged 13−18 years who were familiar with performing AD
were enrolled in the study. Peak Expiratory Flow Rates (PEFR) were measured
using a Peak Flow meter during a cough, huff, and the unsticking, collecting and
evacuating phases of AD. A mean of 3 measurements was taken for each parameter.
This was then compared to their FVC, FEV1 performed by standard methods.
Results: PEFR L/min produced with a cough was less than that produced by
hufﬁng, but did not reach clinical signiﬁcance (203±164.6 vs 249±160.2). This
is consistent with the work by McCarren [1]. The PEFRs increased signiﬁcantly
with each level of AD, unsticking phase = 47.7±17, collecting phase 85±28.6,
evacuating phase 115±31.7. Thus the required PEFR was reached at all levels. The
PEFR with hufﬁng was signiﬁcantly higher than with any phase of AD (P = 0.03),
but coughing did not signiﬁcantly increase PEFR >AD. There was no correlation
between PEFRs with AD and FEV1 (FEV1 median 2.8 L, range 1.93–3.76).
Conclusion: AD generates sufﬁciently high PEFRs to mobilize secretions prox-
imally. Cough does not improve PEFRs >AD, whereas hufﬁng does. Flow rates
generated by AD were not dependent on FEV1, but rather on what patients felt was
effective.
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